Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 347

1.

Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors.

Sekine C, Sugihara T, Miyake S, Hirai H, Yoshida M, Miyasaka N, Kohsaka H.

J Immunol. 2008 Feb 1;180(3):1954-61.

2.

Adenoviral transfer of cyclin-dependent kinase inhibitor genes suppresses collagen-induced arthritis in mice.

Nasu K, Kohsaka H, Nonomura Y, Terada Y, Ito H, Hirokawa K, Miyasaka N.

J Immunol. 2000 Dec 15;165(12):7246-52.

3.

Suppression of arthritis by forced expression of cyclin-dependent kinase inhibitor p21(Cip1) gene into the joints.

Nonomura Y, Kohsaka H, Nasu K, Terada Y, Ikeda M, Miyasaka N.

Int Immunol. 2001 Jun;13(6):723-31.

4.

Direct modulation of rheumatoid inflammatory mediator expression in retinoblastoma protein-dependent and -independent pathways by cyclin-dependent kinase 4/6.

Nonomura Y, Nagasaka K, Hagiyama H, Sekine C, Nanki T, Tamamori-Adachi M, Miyasaka N, Kohsaka H.

Arthritis Rheum. 2006 Jul;54(7):2074-83.

5.

Expression and function of junctional adhesion molecule-C in human and experimental arthritis.

Palmer G, Busso N, Aurrand-Lions M, Talabot-Ayer D, Chobaz-Péclat V, Zimmerli C, Hammel P, Imhof BA, Gabay C.

Arthritis Res Ther. 2007;9(4):R65.

6.

Rhabdoid tumor growth is inhibited by flavopiridol.

Smith ME, Cimica V, Chinni S, Challagulla K, Mani S, Kalpana GV.

Clin Cancer Res. 2008 Jan 15;14(2):523-32. doi: 10.1158/1078-0432.CCR-07-1347.

7.

Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis.

De Bandt M, Ben Mahdi MH, Ollivier V, Grossin M, Dupuis M, Gaudry M, Bohlen P, Lipson KE, Rice A, Wu Y, Gougerot-Pocidalo MA, Pasquier C.

J Immunol. 2003 Nov 1;171(9):4853-9.

8.
9.

Effect of nuclear factor-kappaB inhibition on rheumatoid fibroblast-like synoviocytes and collagen induced arthritis.

Okazaki Y, Sawada T, Nagatani K, Komagata Y, Inoue T, Muto S, Itai A, Yamamoto K.

J Rheumatol. 2005 Aug;32(8):1440-7.

PMID:
16078317
10.

Flavonol-rich RVHxR from Rhus verniciflua Stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritic fibroblast-like synovial cells and in vivo models.

Lee JD, Huh JE, Jeon G, Yang HR, Woo HS, Choi DY, Park DS.

Int Immunopharmacol. 2009 Mar;9(3):268-76. doi: 10.1016/j.intimp.2008.11.005. Epub 2008 Dec 25.

PMID:
19111632
11.

Is Taurolidine a candidate for treatment of rheumatoid arthritis?

Marcinkiewicz J, Głuszko P, Kontny E, Kwaśny-Krochin B, Bobek M, Wierzchowski W, Ciszek M, Maśliński W.

Clin Exp Rheumatol. 2007 Mar-Apr;25(2):211-8.

PMID:
17543144
12.

Cell cycle regulation therapy combined with cytokine blockade enhances antiarthritic effects without increasing immune suppression.

Hosoya T, Iwai H, Yamaguchi Y, Kawahata K, Miyasaka N, Kohsaka H.

Ann Rheum Dis. 2016 Jan;75(1):253-9. doi: 10.1136/annrheumdis-2014-205566. Epub 2014 Aug 27.

PMID:
25165034
13.

An LFA-1 (alphaLbeta2) small-molecule antagonist reduces inflammation and joint destruction in murine models of arthritis.

Suchard SJ, Stetsko DK, Davis PM, Skala S, Potin D, Launay M, Dhar TG, Barrish JC, Susulic V, Shuster DJ, McIntyre KW, McKinnon M, Salter-Cid L.

J Immunol. 2010 Apr 1;184(7):3917-26. doi: 10.4049/jimmunol.0901095. Epub 2010 Feb 26.

14.

Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus.

Zoja C, Casiraghi F, Conti S, Corna D, Rottoli D, Cavinato RA, Remuzzi G, Benigni A.

Arthritis Rheum. 2007 May;56(5):1629-37.

15.

Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis.

Gillooly KM, Pattoli MA, Taylor TL, Chen L, Cheng L, Gregor KR, Whitney GS, Susulic V, Watterson SH, Kempson J, Pitts WJ, Booth-Lute H, Yang G, Davies P, Kukral DW, Strnad J, McIntyre KW, Darienzo CJ, Salter-Cid L, Yang Z, Wang-Iverson DB, Burke JR.

J Pharmacol Exp Ther. 2009 Nov;331(2):349-60. doi: 10.1124/jpet.109.156018. Epub 2009 Aug 3.

16.

Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice.

Koyama K, Hatsushika K, Ando T, Sakuma M, Wako M, Kato R, Haro H, Sugiyama H, Hamada Y, Ogawa H, Nakao A.

Mod Rheumatol. 2007;17(4):306-10. Epub 2007 Aug 20.

PMID:
17694264
17.

Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis.

Lange F, Bajtner E, Rintisch C, Nandakumar KS, Sack U, Holmdahl R.

Ann Rheum Dis. 2005 Apr;64(4):599-605. Epub 2004 Sep 2.

18.

Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines.

Eguchi T, Itadani H, Shimomura T, Kawanishi N, Hirai H, Kotani H.

Mol Cancer Ther. 2009 Jun;8(6):1460-72. doi: 10.1158/1535-7163.MCT-08-1159. Epub 2009 Jun 9.

19.

Recent progress in the discovery and development of cyclin-dependent kinase inhibitors.

Fischer PM, Gianella-Borradori A.

Expert Opin Investig Drugs. 2005 Apr;14(4):457-77. Review.

PMID:
15882121
20.

FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice.

Ohori M, Takeuchi M, Maruki R, Nakajima H, Miyake H.

Naunyn Schmiedebergs Arch Pharmacol. 2007 Jan;374(4):311-6. Epub 2006 Nov 23.

PMID:
17123065
Items per page

Supplemental Content

Write to the Help Desk